Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma

Table 1

The transition of laboratory parameters (e.g., C-reactive protein (CRP), hemoglobin (Hb), albumin (Alb), and interleukin-6 (IL-6)) and the size of the tumor and lymph node in our hospital during the first visit.

	First visit	Before surgery	After surgery	Recurrence	Before tocilizumab	After tocilizumab
CRP (mg/dl)	9.8	18	0.05	2.21	1.89	0.25
Hb (g/dl)	9.2	7.5	12.1	11.3	11.4	10.4
Alb (mg/dl)	3.5	2.3	4	4.2	4.1	3.9
IL-6 (pg/dl)	51.5	N/A	0.935	N/A	12.4	N/A
Tumor size (mm)	49	55	0	19	23	51
Lymph node size (mm)	19	22	21	27	27	27

Before surgery: the primary tumor; after surgery: tumor recurrence; N/A: not applicable.